KOD - Kodiak Sciences Inc.

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $63.75 DETAILS

Stock News

Why One Healthcare Fund Increased Its Kodiak Sciences Stake Amid an Eye-Popping Rally

This clinical-stage biotech develops innovative retinal disease therapies, with its lead candidate advancing through late-stage trials.

May 17, 2026 11:57 AM • fool.com

Kodiak's Q1 Loss Wider Than Expected, Pipeline Development in Focus

KOD posts a wider Q1 loss as research & development spending rises, while positive phase III Zenkuda data accelerate the regulatory plans.

May 08, 2026 09:41 AM • zacks.com

Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results

PALO ALTO, Calif., May 7, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the third quarter ended March 31, 2026.

May 07, 2026 12:00 PM • prnewswire.com

Kodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific Conferences

Clinical results of KSI-101 in macular edema secondary to inflammation (MESI) from a tertiary care uveitis practice demonstrate outcomes consistent with results from the U.S. Phase 1b APEX study, supporting continued global development and expansion of the Phase 3 PEAK and PINNACLE program into Asia. Ongoing advancement of bispecific therapies in geographic atrophy and ocular inflammatory disease; preclinical data continue to support a multi-target approach to address limitations of current single-target therapies.

Apr 30, 2026 08:23 PM • prnewswire.com

Kodiak Sciences (KOD) Up 2% Since Last Earnings Report: Can It Continue?

Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock?

Apr 30, 2026 08:31 AM • zacks.com

Kodiak Q4 Loss Wider Than Expected, Pipeline Development in Focus

KOD posts wider Q4 loss. However, its pipeline advances, with strong phase III data for Zenkuda driving accelerated regulatory plans.

Apr 01, 2026 09:46 AM • zacks.com

Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results

PALO ALTO, Calif., March 31, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2025.

Mar 31, 2026 12:45 PM • prnewswire.com

Kodiak Sciences: Road To $120

Kodiak Sciences' stock (NASDAQ: KOD) experienced a substantial 62% surge last week, elevating the stock to $37 and increasing its market capitalization to $2.3 billion. This impressive momentum was fueled by robust Phase 3 GLOW2 results for Zenkuda (tarcocimab), an experimental treatment aimed at retinal vascular disorders.

Mar 30, 2026 06:00 AM • forbes.com

Kodiak Sciences (NASDAQ:KOD) Reaches New 52-Week High – Time to Buy?

Kodiak Sciences Inc. (NASDAQ: KOD - Get Free Report) shares hit a new 52-week high during trading on Thursday. The company traded as high as $36.84 and last traded at $36.0160, with a volume of 3075248 shares. The stock had previously closed at $22.75. More Kodiak Sciences News Here are the key news stories impacting

Mar 28, 2026 12:23 AM • defenseworld.net

KOD Stock Soars on Promising Phase III Data for Eye Disease Candidate

Kodiak Sciences rallies 75% as phase III GLOW2 data show Zenkuda's strong efficacy, safety and risk reduction in diabetic retinopathy patients.

Mar 27, 2026 09:11 AM • zacks.com

Kodiak Sciences Stock Is Surging Friday: What's Driving The Action?

Investors appear to be responding to both the strength of the data and the possibility of a faster path toward a biologics license application, or BLA. Here's what investors need to know.

Mar 27, 2026 06:40 AM • benzinga.com

Kodiak Sciences shares surge after eye drug succeeds in late-stage study

Shares of drug developer Kodiak Sciences jumped 52% before the bell on Thursday after its experimental drug met the main goal in a ‌late-stage study in patients with diabetes-related eye damage.

Mar 26, 2026 04:12 AM • reuters.com

Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda™ (tarcocimab tedromer) Over Sham

Building on the success of GLOW1 and with all patients on a 6-month dosing interval, Zenkuda (tarcocimab tedromer) demonstrated superiority to sham with 62.5% of Zenkuda-treated patients achieving a ≥2-step improvement in diabetic retinopathy severity score (DRSS) compared to 3.3% of sham-treated patients (p

Mar 26, 2026 02:00 AM • prnewswire.com

Investment Firm Doubles Down on Biotech Stock, Adds 386,000 Shares, According to Recent SEC Filing

This clinical-stage biotech targets retinal diseases with late-stage drug candidates and a focused pipeline in ophthalmology.

Mar 09, 2026 05:46 AM • fool.com

Kodiak Sciences Inc. (NASDAQ:KOD) Receives $28.29 Consensus Target Price from Brokerages

Kodiak Sciences Inc. (NASDAQ: KOD - Get Free Report) has received an average recommendation of "Moderate Buy" from the eight analysts that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company.

Mar 04, 2026 09:52 PM • defenseworld.net

Kodiak Sciences Stock Up 480% as One Fund Discloses $53 Million Buy

Baker Bros. Advisors increased its Kodiak Sciences stake by 2,608,696 shares; the estimated trade size was $53.42 million.

Feb 23, 2026 08:20 AM • fool.com

Kodiak Sciences (NASDAQ:KOD) Shares Down 5.9% – What’s Next?

Kodiak Sciences Inc. (NASDAQ: KOD - Get Free Report)'s stock price dropped 5.9% on Friday. The stock traded as low as $25.32 and last traded at $25.1010. Approximately 60,109 shares changed hands during trading, a decline of 92% from the average daily volume of 725,091 shares. The stock had previously closed at $26.67. Analyst Upgrades

Feb 21, 2026 11:36 PM • defenseworld.net

Inside a $58 Million Bet on Kodiak Amid $184 Million Offering and Phase 3 Readouts Ahead

Connecticut-based Braidwell bought 2,072,788 shares in Kodiak Sciences in the fourth quarter. The quarter-end position value increased by $57.96 million, reflecting the establishment of the new position.

Feb 19, 2026 12:14 PM • fool.com

Abbott Laboratories: A Key Reduction in Robert Bruce's Portfolio

Exploring the Strategic Moves of a Seasoned Value Investor Robert Bruce (Trades, Portfolio) recently submitted the 13F filing for the fourth quarter of 2025, p

Feb 13, 2026 01:01 PM • gurufocus.com

KOD Stock Up 24% in 3 Months: Here's What You Need to Know

Kodiak Sciences' shares jump 24% in three months as late-stage retinal programs advance and fresh funding extends its cash runway, fueling investor confidence.

Feb 06, 2026 07:35 AM • zacks.com